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OBJECTIVE — Pericardialadiposetissue(PAT),aregionalfatdepotthatsurroundstheheart,
is associated with an unfavorable cardiometabolic risk factor proﬁle. The associations among
PAT, cardiometabolic risk factors, and coronary artery calciﬁcation (CAC) and abdominal aortic
artery calciﬁcation (AAC) in African American populations have not been explored.
RESEARCH DESIGN AND METHODS — A total of 1,414 African Americans (35%
men; mean  SD age 58  11 years) drawn from the Jackson Heart Study (JHS) underwent
multidetectorcomputedtomographyassessmentofabdominalvisceraladiposetissue(VAT)and
PAT between 2007 and 2009. Cardiometabolic risk factors, CAC, and AAC were examined in
relation to increments of PAT and VAT.
RESULTS — PAT was signiﬁcantly correlated with BMI, waist circumference, and VAT (r 
0.35, 0.46, and 0.69; all P  0.0001). PAT (per 1-SD increase) was associated with elevated
levels of systolic blood pressure (P  0.04), fasting glucose, triglycerides, and C-reactive protein
and lower levels of HDL (all P values0.0001). PAT was also associated with metabolic syn-
drome(oddsratio[OR]1.89;P0.0001),hypertension(1.48;P0.0006),anddiabetes(1.40;
P  0.04); all associations were diminished after further adjustment for VAT (most P  0.05).
However, the association of PAT with CAC but not with AAC remained signiﬁcant (OR 1.34
[95% CI 1.10–1.64]; P  0.004) after multivariable and VAT adjustment.
CONCLUSIONS — PAT is signiﬁcantly correlated with most cardiometabolic risk factors
and CAC in the JHS cohort. The results suggest that PAT is an important VAT depot that may
exert a local effect on the coronary vasculature.
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P
ericardial adipose tissue (PAT) is an
ectopic fat depot associated with
measuresofadiposityandmetabolic
risk factors and a predictor of coronary
heart disease events (1–5). As a newly
proposed marker of the visceral fat depot,
PAT may exert a paracrine effect on
nearbyanatomicstructuresbyactivelyse-
creting a number of proatherogenic and
proinﬂammatory hormones, cytokines,
and chemokines (1,6,7). However, the
understanding of the relationship be-
tweentheextra-abdominalvisceralfatde-
pot including PAT and cardiovascular
disease (CVD) risk factors in nonwhite
populations is lacking. In particular, Afri-
can Americans have much higher rates of
obesity and have experienced different
levels of CVD risk in relation to obe-
sity (8,9). Therefore, additional data are
needed to clarify the role of PAT in rela-
tion to CVD in this population. Thus, to
better understand the impact of obesity
onmetabolicriskfactorsinAfricanAmer-
icans, the purpose of this study was to
examine the associations of computed to-
mography (CT) measures of PAT with
other measures of adiposity, such as BMI
and abdominal visceral adipose tissue
(VAT) as well as cardiometabolic risk
factors.
RESEARCH DESIGN AND
METHODS— The JHS recruited
5,301 African Americans from the Jack-
son, Mississippi, metropolitan area be-
tween September 2000 and March 2004.
Thecohortwascomposedoffourcompo-
nents: 1) 31% of the cohort members
were participants from the Atherosclero-
sis Risk in Communities (ARIC) study
recruited to the JHS; 2) 30% were repre-
sentative community volunteers who met
census-derived age, sex, and socioeco-
nomic status eligibility criteria from the
Jackson, Mississippi, metropolitan area;
3) 17% were randomly ascertained from
the Jackson, Mississippi, metropolitan
area through methods described previ-
ously(10,11);and4)22%wereintheJHS
Family Study. The sampling frame for
the family study was participants in any
one of the ARIC, random, or volunteer
samples whose family size met eligibility
requirements as detailed previously
(10,11). The cohort consisted of 5,035
adults aged 35–84 years old, and an ad-
ditional 266 participants (251 partici-
pants aged 21–34 and 15 participants
aged 85) who were added as a part of
the JHS Family Study. This resulted in a
ﬁnal age range of 21 to 94 years (10,11).
The present study included participants
who underwent multidetector CT scan-
ning from 2007 to 2009 as a part of the
second JHS examination.
Overall, 4,200 participants attended
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(35% men) underwent multidetector CT
assessment for VAT and PAT. Of these
1,414 participants, 1,402 had a complete
covariate proﬁle, 1,378 had an available
measure of VAT, and 1,298 were free of
CVD. The study protocol was approved
by the institutional review boards of the
participating institutions: the University
of Mississippi Medical Center, Jackson
State University, and Tougaloo College.
All of the participants provided informed
consent.
Multidetector CT scan protocol for
measuring adiposity
The research CT protocol included the
heart and lower abdomen, using a
16-channel multidetector CT system
equipped with cardiac gating (Lightspeed
16 Pro; GE Healthcare, Milwaukee, WI).
Quality control and image analysis was
performed at a core reading center (Wake
Forest University School of Medicine,
Winston-Salem, NC). The protocol in-
cluded scout images, one electrocardio-
gramgatedseriesoftheentireheart,anda
series through the lower abdomen from
L3 to S1 used for assessing VAT. The es-
timated average whole-body effective
dose for the entire protocol was 4 mSv.
The scanning procedure for cardiac gated
CT scans of the coronary arteries was
based on the standard protocols devel-
opedasapartoftheNationalHeart,Lung,
and Blood Institute’s Multi-Ethnic Study
of Atherosclerosis (MESA) and Coronary
ArteryRiskDevelopmentinYoungAdults
(CARDIA) studies.
PAT measurement was performed on
the CT images after segmentation of the
heart and surrounding adipose tissue
from the remainder of the thorax using
speciﬁcanatomiclandmarks.Becauseitis
difﬁculttodistinguishpericardialfatfrom
epicardial fat by the CT images, the PAT
in our study was measured by combina-
tion of pericardial fat and epicardial fat.
For pericardial fat volume, 18 slices, 2.5
mmthick,starting1.5cmaboveandend-
ing 3.0 cm below the superior extent of
the left main coronary artery were in-
cluded for coverage of 4.5 cm along the
head-foot (z-axis) of the individual. The
anteriorborderofthevolumewasdeﬁned
by the chest wall and the posterior border
by the aorta and the bronchus. This re-
gion of the heart was selected because it
includes the pericardial adipose tissue lo-
cated around the major epicardial coro-
nary arteries (left main coronary, left
anterior descending, right coronary, and
circumﬂex arteries). Volume Analysis
software (Advantage Windows; GE
Healthcare, Waukesha, WI) was used to
segment and characterize each individual
voxel as a tissue attenuation of fat using
a threshold range of 190 to 30
Hounsﬁeld units. The PAT volume was
the sum of all pericardial fat voxels over
the 4.5-cm volume (cubic centimeters/
4.5 cm). A similar approach was used
for measuring abdominal fat depots.
Twenty 2.5-mm-thick slices centered
on the lumbar disk space at L4–L5 were
analyzed. In this study, a randomly se-
lected sample of 60 participants, the
correlation coefﬁcient between two dif-
ferent readers was 0.95 for VAT and
subcutaneous adipose tissue and 0.96
for PAT, indicating excellent reproduc-
ibility of CT imaging measurements.
Coronary artery calcium and
abdominal aortic calcium
measurements
CT images were read by experienced and
trained technologists for quantity of cor-
onary artery calcium (CAC) and abdomi-
nal aortic calcium (AAC). The Agatston
score, modiﬁed to account for slice thick-
ness, was used to quantify the amount of
calciﬁed artery plaque, which was com-
putedbymultiplyingeachlesion(area)by
a weighted attenuation score (in
Hounsﬁeld units) on a TeraRecon Aquar-
ius Workstation (TeraRecon, San Mateo,
CA). The reproducibility for CAC and
AAC was 0.99. The presence of CAC and
AAC was deﬁned as Agatston score 0.
Risk factors and covariate
assessment
Risk factors and covariates were measured
at examination 1 (2000–2004). BMI was
deﬁned as weight in kilograms divided by
the square of height in meters. Two mea-
sures of the waist (at the level of the umbi-
licus,intheuprightposition)wereaveraged
to determine baseline waist circumference
for each participant. Fasting blood samples
were collected according to standardized
procedures, and the assessments of plasma
glucose, lipids, and C-reactive protein
(CRP) were processed at the Central Labo-
ratory (University of Minnesota) as de-
scribed previously (10,11). Sitting blood
pressure was measured twice at 5-min in-
tervals, and the average of two measure-
ments was used for analysis.
Participants were considered to have
dyslipidemia if their HDL cholesterol lev-
els were 40 mg/dl in men and 50 mg/dl
in women and/or if they had LDL choles-
terol 160 mg/dl or used lipid-lowering
medication. Participants were considered
to be hypertensive if they were taking an-
tihypertensive medications, if they self-
reported a diagnosis of hypertension,
and/oriftheirsystolicpressurewas140
mmHg or diastolic pressure was 90
mmHg. Diabetes was deﬁned as a fasting
plasmaglucoselevel126mg/dlortreat-
ment with insulin or a hypoglycemic
agent. Modiﬁed National Cholesterol Ed-
ucation Program Adult Treatment Panel
III criteria were used to deﬁne the meta-
bolic syndrome (8,12) .
The JHS Physical Activity Cohort
(JPAC) survey, which was derived from the
modiﬁed ARIC physical activity survey was
administered by trained interviewers at a
homevisitprecedingtheJHSclinicalexam-
ination.Thetotalphysicalactivityscorewas
calculated as the sum of the four different
domains of physical activity (active living,
work, home and garden, and sport and ex-
ercise indexes) (13). Alcohol use was de-
ﬁned as consumption of alcoholic
beverages within the past 12 months. Cur-
rentsmokingstatuswasdeﬁnedassmoking
at the time of the interview.
Statistical analysis
PAT was normally distributed, and CRP
was normalized by logarithmic transfor-
mation and the central tendency and
spread represented by the median and in-
terquartile ranges. Age-adjusted Pearson
correlations of PAT and VAT were per-
formed with each of the metabolic risk
factors including systolic and diastolic
blood pressure, fasting plasma glucose
and insulin, triglycerides, HDL choles-
terol, and CRP, hypertension, diabetes,
and dyslipidemia. To estimate the stan-
dardized effect size of PAT on continuous
risk factors or the odds ratio (OR) on di-
chotomized risk factor prevalence, PAT
was standardized to a mean of 0 and a SD
of 1. Next, a multivariable regression
model was constructed with PAT as the
independentvariableandeachofthemet-
abolic risk factors as the dependent vari-
able. Three models were generated in
stages: 1) the multivariable-adjusted
models,forwhichcovariatesinallmodels
included age, sex, smoking and alcohol,
treatment for hypertension, diabetes, and
dyslipidemia; 2) a second model in which
the ﬁrst model was additionally adjusted
forBMI;and3)aﬁnalmodel,inwhichthe
ﬁrst model was additionally adjusted for
VAT. Sex interactions were examined in
the ﬁrst model. Sex interactions were not
signiﬁcant in this study (all P  0.05),
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and men combined.
The association between PAT and the
presence of CAC and AAC was assessed
using logistic regression analysis to esti-
mate the OR of the presence of CAC and
AAC per 1-SD increase in PAT after ad-
justment for 1) age and sex; 2) age, sex,
and VAT; 3) age, sex, smoking, alcohol,
total and HDL cholesterol, systolic blood
pressure, diabetes, hypertension treat-
ment,andlipidtreatment;and4)model3
plus VAT. P  0.05 was considered sig-
niﬁcant. All computations were per-
formed by SAS software (version 9.2, SAS
Institute, Cary, NC).
RESULTS— Overall, 925 women and
489 men were available for analysis. The
mean age of the study sample was 54
years. The mean  SD PAT volume was
67.1  29 cm
3 in women and 79.8 
37.1 cm
3 in men (Table 1). Approxi-
mately 52% of participants were obese,
61% had hypertension, 39% had meta-
bolic syndrome, and 15% had diabetes.
Correlations with PAT
Age- and VAT-adjusted correlation coef-
ﬁcients of PAT with metabolic risk factors
are displayed in Table 2. PAT was corre-
latedtoallofthecardiometabolicriskfac-
tors tested, with the notable exception of
total cholesterol and diastolic blood pres-
sure. PAT was also inversely related to
physical activity score. However, the par-
tial correlation coefﬁcients of PAT with
cardiometabolic risk factors did not re-
main signiﬁcant after additional adjust-
ment for VAT.
Multivariable-adjusted regression
with PAT and metabolic risk factors
To investigate the strength of the associa-
tion of PAT with both continuous and di-
chotomous metabolic risk factors, we
performed multivariable regressions as
summarized in Table 3. We observed sig-
niﬁcant associations per 1-SD increment
of PAT and continuous measures of sys-
tolic blood pressure, fasting glucose, tri-
glycerides,HDLcholesterol,andlogCRP.
However, the signiﬁcant effect of PAT on
these risk factors became weaker or di-
minished when BMI or VAT appeared in
the same model (Table 3). Signiﬁcant as-
sociations with PAT were also observed
for dichotomous metabolic traits. The
ORs of metabolic syndrome (1.89), hy-
pertension(1.48),anddiabetes(1.40)per
1-SD increase in PAT were signiﬁcant (all
P0.05).Theserelationsbecameweaker
ordiminishedafteradditionaladjustment
for BMI or VAT (Table 4).
Logistic regression analysis with
PAT and CAC
Generally, men had a slightly higher per-
centage for the presence of CAC than
women (49 vs. 41%) with a similar value
for AAC (65 vs. 61%). The relationship
between PAT and the presence of CAC
was found to be signiﬁcant in the mini-
mally adjusted model (OR 1.37 [95% CI
1.20–1.56]; P  0.0001). This associa-
tion was not materially different with ad-
ditional adjustment for VAT (OR 1.37
[1.15–1.64]; P  0.0004) and persisted
after additional adjustment for VAT and
CVD risk factors (1.34 [1.10–1.64]; P 
0.004), including smoking, alcohol, total
and HDL cholesterol, systolic blood pres-
sure, diabetes, hypertension treatment,
and lipid treatment. Conversely, there
wasnoassociationbetweenPATandAAC
inthemultivariable-adjustedmodel(1.03
[0.82–1.29]; P  0.80).
Table 1—Clinical characteristics of study participants
Women Men
n 925 489
Age (years) 60  11 58  11
Pericardial fat (cm
3) 67.1  29 79.8  37.1
Visceral abdominal fat (cm
3) 789.5  363 850.4  402.5
BMI (kg/m
2) 32.4  7.0 29.4  5.1
Waist circumference (cm) 99.2  16.2 100.2  12.9
CAC present 41 (372) 49 (224)
AAC present 61 (553) 65 (301)
Height (cm) 164.2  6.4 178.1  6.6
Triglyceride (mmol/l) 1.12  0.56 1.21  0.69
HDL cholesterol (mmol/l) 1.41  0.36 1.16  0.29
Total cholesterol (mmol/l) 5.21  1.04 5.05  1.02
Systolic blood pressure (mmHg) 124.4  16.5 125.9  15.6
Diastolic blood pressure (mmHg) 77.3  9.6 82.1  9.8
Fasting glucose (mmol/l) 5.33  1.26 5.41  1.44
CRP (nmol/l) 3.3 (1.3, 6.7) 1.3 (0.6, 2.9)
Obesity (BMI 30 kg/m
2) 58.5 38.5
Diabetes 15.6 13.5
Metabolic syndrome 41.2 33.2
Hypertension 62.5 59.2
Current smokers 7.9 12.3
Alcohol use 37.2 60.1
Physical activity score 8.3  2.4 8.9  2.6
Data are means  S D ,%( n), or median (25th, 75th percentile) unless indicated otherwise.
Table 2—Partial Pearson correlation coefﬁcients between pericardial fat volumes and meta-
bolic risk factors
Age-adjusted
Age- and
VAT-adjusted
BMI 0.35† 0.01
Waist circumference 0.46† 0.08*
Visceral abdominal fat 0.69† NA
Triglycerides 0.23† 0.05
HDL cholesterol 0.20† 0.04
Total cholesterol 0.01 0.01
Systolic blood pressure 0.09† 0.01
Diastolic blood pressure 0.07* 0.04
Fasting glucose 0.14† 0.02
Log CRP 0.17† 0.01
Physical activity score 0.11† 0.02
*P  0.05; †P  0.0001. NA, not available.
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Principal ﬁndings
AmongtheJHScohortof1,414participants
undergoing multidetector CT scanning,
PATwasfoundtobesigniﬁcantlyassociated
withcardiometabolicriskfactors.However,
most of the observed associations were at-
tenuated or diminished with additional ad-
justment for BMI or VAT, suggesting that
PAT is not more strongly correlated to car-
diometabolic risk factors than VAT or BMI.
In contrast, commensurate with its pro-
posed primary role as a locally acting fat
depot, PAT was predominantly associated
withCACbutnotwithAACevenafterVAT
and other relevant CVD risk factors were
accounted for.
Our ﬁndings have important implica-
tions for the role of PAT in relation to car-
diometabolic risk factors and vascular
calciﬁcation.Anatomically,thecoronaryar-
teriesandthemyocardiumofboththeright
and left ventricles are surrounded by or in
direct contract with this small fat depot.
Consequently, this close proximity of PAT
to the coronary artery and the underlying
myocardium may exert a local toxic effect
on the nearby organs rather than a systemic
effect on cardiometabolic risk factors. Our
data support the hypotheses that PAT is as-
sociated with cardiometabolic risk factors
becauseofsharedriskfactorswithVATand
that the independent association of PAT
with CAC is probably due to its close ana-
tomicrelationshipwiththecoronaryvascu-
lature. More importantly, despite lower
amounts of VAT at similar levels of BMI in
African Americans (14), the associations of
PAT with cardiometabolic risk factors and
CACfoundinthisAfricanAmericancohort
isconsistentwiththeﬁndingsfromtheFra-
mingham Heart Study (1–5).
In the context of current literature
PAT has been found in several clinical
studies to be signiﬁcantly associated with
clinicalkeycomponentsofmetabolicsyn-
drome and insulin resistance including
BMI, waist circumference, elevated levels
of blood pressure, glucose, LDL choles-
terol, HDL cholesterol, triglycerides, and
inﬂammatory cytokines including high-
sensitivityCRP(3,4,7,15),andithasbeen
proposed as a new indicator of cardiovas-
cular risk (4). However, such an associa-
tion may result from the systemic effects
of the abdominal visceral fat depot be-
cause PAT is highly correlated with ab-
dominal visceral fat. Furthermore, a large
sample from the Framingham Heart Study
demonstrated that the association of PAT
with these cardiometabolic risk factors was
weakerordiminishedwhenVATwastaken
into account (1,3). These data suggest that
PAT may be a residual marker of visceral
adiposity.
As a part of the metabolically active
visceral fat depot, PAT is an important
local source of free fatty acids and a num-
ber of proatherogenic, proinﬂammatory,
and prothrombotic hormones, and cyto-
kines,includingleptin,monocytechemo-
tacticprotein-1,interleukin-6,andtumor
necrosis factor- (6,16–19). In addition,
PAT is usually located in close proximity
to the coronary vasculature compared
withotherfatdepots.Suchdistinguishing
biochemical properties and the unique
anatomic location of PAT are hypothe-
sized to enhance its paracrine role in the
development of coronary atherosclerosis
(1,20,21). Therefore, a local interaction
between PAT and the nearby coronary
vasculature may explain the association
between PAT with CAC observed in our
data.
Strengths and limitations
Strengths of this study include the large
sample size from a community-based co-
hort of African Americans, simultaneous
volumetric quantiﬁcation of PAT and
VAT,andmultipleadjustmentsforpoten-
tial confounders. Limitations include 1)
the cross-sectional study design, which
limits our ability to infer causality; 2)
the primarily African American sample
(although this may be seen as a limita-
tion of the current study, it is important
to note that our results are consistent
with the ﬁndings from the Framingham
Heart Study [1], suggesting that our
ﬁndings may apply across the ethnic
groups); and 3) the potential misclassi-
ﬁcation of PAT due to combined mea-
surement of pericardial and epicardial
fat inherent in our methodology. In ad-
dition, because the CT-measured PAT
and VAT were collected several years
after clinical data were collected, this
time gap between clinical data collected
and CT measurements could result in
misclassiﬁcation of risk factors. However,
this limitation should not affect the relative
association among PAT, VAT, and CAC,
which were measured contemporaneously
on the same CT scans.
In summary, PAT is correlated with
most cardiometabolic risk factors but not
Table 3—Multivariable adjusted regression coefﬁcients between pericardial fat (per 1 SD) and metabolic risk factors
Model MV adjusted P value MV adjusted  VAT P value MV adjusted  BMI P value
Systolic blood pressure (mmHg) 0.95  0.46 0.04 0.46  0.61 0.45 0.46  0.49 0.34
Diastolic blood pressure (mmHg) 0.20  0.29 0.48 0.03  0.38 0.95 0.03  0.31 0.91
Fasting plasma glucose (mmol/l) 2.09  0.63 0.0009 0.66  0.84 0.43 1.60  0.68 0.02
Triglycerides (mmol/l) 9.25  1.59 0.0001 1.11  2.09 0.59 7.14  1.72 0.0001
HDL cholesterol (mmol/l) 1.95  0.41 0.0001 0.20  0.54 0.71 0.79  0.47 0.07
Log CRP 0.28  0.04 0.0001 0.11  0.05 0.03 0.09  0.04 0.02
Data are multivariable (MV) regression coefﬁcients (means  SE) adjusted for age, sex, smoking, alcohol and treatment of hypertension, diabetes, or dyslipidemia.
Table 4—Multivariable ORs adjusted for hypertension, diabetes, and metabolic syndrome with an increase in pericardial fat (per 1 SD)
Model MV adjusted P value MV adjusted  VAT P value MV adjusted  BMI P value
Hypertension 1.48 (1.18–1.84) 0.0006 1.41(1.05–1.91) 0.03 1.44(1.13–1.83) 0.003
Diabetes 1.40(1.01–1.94) 0.04 1.06 (0.67–1.69) 0.78 1.29(0.90–1.86) 0.16
Metabolic syndrome 1.89 (1.62–2.21) 0.0001 1.32 (1.01–1.60) 0.006 1.48(1.25–1.74) 0.0001
Data are multivariable (MV) ORs (95% CI) adjusted for age, sex, smoking, alcohol, and treatment of hypertension, diabetes, or dyslipidemia.
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signiﬁcantly associated with CAC, sug-
gesting that PAT may exert a local toxic
effect on the coronary vasculature in the
JHS cohort.
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